mn rgp120/hiv-1
Vaccineexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 1999 (NCT00006327)
Timeline
Indications
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mn rgp120/hiv-1
- mn rsgp120/hiv-1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00011037 | Phase 2 | Feb 8, 2001 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000809 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00000866 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00002402 | Phase 1 | Nov 2, 1999 | VaxGen |
| NCT00006327 | Phase 3 | Mar 1, 1999 | VaxGen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 3 | 3 | 1999 |
| VaxGen | For profit | 2 | 2 | 2 | 1999 |
2 organizations
Page 1 / 1